Niels Svenstrup Sells 10,000 Shares of PepGen Inc. (NASDAQ:PEPG) Stock

PepGen Inc. (NASDAQ:PEPGGet Free Report) SVP Niels Svenstrup sold 10,000 shares of the firm’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $13.41, for a total transaction of $134,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

PepGen Stock Down 3.6 %

NASDAQ:PEPG opened at $13.16 on Friday. The company has a 50-day moving average of $13.16 and a 200-day moving average of $10.13. PepGen Inc. has a 52 week low of $3.72 and a 52 week high of $17.51.

PepGen (NASDAQ:PEPGGet Free Report) last released its quarterly earnings data on Wednesday, March 6th. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.19. Equities research analysts predict that PepGen Inc. will post -2.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PepGen

Institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new position in PepGen during the 1st quarter valued at about $30,000. Allspring Global Investments Holdings LLC bought a new position in PepGen during the 3rd quarter valued at about $33,000. Rathbones Group PLC bought a new position in PepGen during the 3rd quarter valued at about $315,000. Artal Group S.A. bought a new position in PepGen during the 1st quarter valued at about $2,940,000. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in PepGen by 18.3% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 680,000 shares of the company’s stock valued at $3,454,000 after purchasing an additional 105,000 shares during the last quarter. 58.01% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PEPG has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $26.00 price target on shares of PepGen in a research report on Wednesday. Wedbush restated an “outperform” rating and issued a $20.00 price target on shares of PepGen in a research report on Wednesday.

Check Out Our Latest Research Report on PEPG

PepGen Company Profile

(Get Free Report)

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.

Featured Articles

Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.